Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
77.86
-2.46 (-3.06%)
At close: Mar 13, 2026, 4:00 PM EDT
77.76
-0.10 (-0.13%)
After-hours: Mar 13, 2026, 7:46 PM EDT
Dianthus Therapeutics Revenue
In the year 2025, Dianthus Therapeutics had annual revenue of $2.04M, down -67.35%. Dianthus Therapeutics had revenue of $284.00K in the quarter ending December 31, 2025, a decrease of -78.58%.
Revenue (ttm)
$2.04M
Revenue Growth
-67.35%
P/S Ratio
1,700.65
Revenue / Employee
$22,130
Employees
92
Market Cap
3.46B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.04M | -4.20M | -67.35% |
| Dec 31, 2024 | 6.24M | 3.41M | 120.63% |
| Dec 31, 2023 | 2.83M | -3.59M | -55.96% |
| Dec 31, 2022 | 6.42M | 4.94M | 334.76% |
| Dec 31, 2021 | 1.48M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ACADIA Pharmaceuticals | 1.07B |
| Legend Biotech | 1.03B |
| Corcept Therapeutics | 761.41M |
| ADMA Biologics | 510.17M |
| NewAmsterdam Pharma Company | 22.50M |
| Centessa Pharmaceuticals | 15.00M |
| Crinetics Pharmaceuticals | 7.70M |
DNTH News
- 1 day ago - Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 3 days ago - Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering - GlobeNewsWire
- 3 days ago - Dianthus Therapeutics: Go Decision For CIDP Program Warrants Continued Buy Rating - Seeking Alpha
- 4 days ago - Dianthus Therapeutics, Inc. (DNTH) Discusses Interim Responder Analysis and Early Go Decision for CAPTIVATE Trial in CIDP Transcript - Seeking Alpha
- 4 days ago - Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering - GlobeNewsWire
- 4 days ago - Dianthus Therapeutics Stock Rallies—Rare Disease Study Success Fuels Optimism - Benzinga
- 4 days ago - Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results - GlobeNewsWire
- 4 days ago - Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - GlobeNewsWire